A comparative effectiveness program launched by Geisinger Health has reportedly slowed the rapid increase in biologic spending, according to an HFMA report.
According to the report, Geisinger Health Plan’s spending on biologics accounted for about 35.9 percent of its total drug spending in 2018, despite the high-cost drugs representing only 0.77 percent of its drug claims.
Geisinger Health Plan Chief Medical Officer John Bulger said the program has produced solid results.
“We though we were going to up to about 50% [of drug spending] being biologics, and we actually bent that curve,” Bulger told HFMA. “We are seeing definite savings for the last year.”
To read the full report on HFMA, click here.
